The Clinical Study of Adalimumab Combined With Other Anti-tumor Therapy as a Treatment for Resectable Non-small Cell Lung Cancer

This study is an open-label, multicenter phase II clinical trial of adebelizumab combined with other anti-tumor therapies in patients with non-small cell lung cancer. The aim of this study was to evaluate the safety, tolerability and efficacy of adebelizumab combined with other anti-tumor therapies in patients with resectable non-small cell lung cancer ( NSCLC )

NCT Number	NCT07704645
Lead Sponsor	Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Conditions	Resectable Non-small Cell Lung Cancer
Enrollment	180 participants
Start Date	2026-08
Primary Completion	2028-06 (estimated)
Study Completion	2029-12 (estimated)
Updated on ClinicalTrials.gov	2026-07-15